All In MedTech

Device Trial Radar · NCT05904548

Atrial Flutter Ablation in the iCMR

Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

91

Planned (sponsor's estimate)

Start

Jun 20, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Imricor Medical SystemsNot on our public-company list
Sponsor type
Industry
First posted
Jun 15, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The VISABL-AFL clinical investigation is a prospective, single-arm, multi-center, interventional, Investigational Device Exemption (IDE) trial. The primary objectives of VISABL-AFL are to assess the safety and efficacy of radiofrequency (RF) ablation of type-I atrial flutter performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.

Conditions

  • Atrial Flutter Typical

Interventions

  • RF AblationDevice

    RF ablation for type I atrial flutter under iCMR guidance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Efficacy Endpoint: Bi-directional block confirmationTime frame: Time of procedure, following delivery of last ablation energy delivery point

1 more outcomes with a free account

Locations

6 sites in 4 countries. Site status is shown where the registry gives one.

  • Johns Hopkins University (JHU)

    Baltimore, Maryland · Recruiting

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.